All In Biotech

Drug Trial Radar · NCT04924322

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill Children

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

May 11, 2022

Primary completion

Apr 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's Hospital Colorado; Children's Hospital of Philadelphia; BJC HealthCare; Medical College of Wisconsin; Children's of Alabama; Golisano Children's Hospital; Maria Fareri Children's Hospital; Nationwide Children's Hospital; New York Presbyterian Hospital; Penn State University; University of Iowa; Johns Hopkins All Children's Hospital; University of Oklahoma; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Children's Hospital of Illinois at Peoria; Hassenfeld Children's Hospital
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.

Conditions

  • Deep Venous Thrombosis

Interventions

  • EnoxaparinDrug

    Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of children with CADVTTime frame: Up to removal of CVC (maximum of 28 days)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Yale-New Haven Children's Hospital

    New Haven, Connecticut · Recruiting

  • University of Florida -UF Health

    Gainesville, Florida · Recruiting

  • Johns Hopkins All Children's

    St. Petersburg, Florida · Recruiting

  • Children's Hospital of Illinois at OSF Saint Francis Medical Center

    Peoria, Illinois · Recruiting

  • Stead Family Children's Hospital

    Iowa City, Iowa · Recruiting

  • Children's Hospital St. Louis

    St Louis, Missouri · Recruiting

  • Hassenfeld Children's Hospital

    New York, New York · Recruiting

  • New York Presbyterian Hospital

    New York, New York · Recruiting

  • Golisano Children's Hospital

    Rochester, New York · Recruiting

  • Maria Fareri Children's Hospital

    Valhalla, New York · Recruiting

  • UH Rainbow Babies & Children's Hospital

    Cleveland, Ohio · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Withdrawn

  • University of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • Penn State Hershey Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Dell Children's Medical Canter

    Austin, Texas · Recruiting

  • UTSW Medical Center; Children's Medical Center of Dallas

    Dallas, Texas · Recruiting

  • Children's Hospital of Richmond

    Richmond, Virginia · Withdrawn

  • Children's Hospital Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.